Q-omics provides the consensus-scored SNORA59B profile across patient tissues and cancer cell-line models. SNORA59B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SNORA59B is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SNORA59B RNA expression shows 9,715 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight UCEC, KIRC, and SARC as cancer lineages where SNORA59B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA59B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA59B survival associations across molecular data types. SNORA59B RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA59B RNA expression–survival associations across cancer types. High SNORA59B expression shows unfavorable associations in READ, HNSC and LGG, but favorable associations in UCEC, BRCA and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for SNORA59B RNA expression.
This table summarizes SNORA59B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA59B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA59B shows lower tumor expression in LUSC and KICH and higher tumor expression in KIRC, LIHC, UCEC and THCA. The KIRC box plot shows higher SNORA59B RNA expression in tumor versus normal tissue (log2 FC = +0.207, t-test p < 0.001).
This table shows molecular features associated with SNORA59B in patient tissues and cancer cell lines. In patient samples, SNORA59B shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
